Human papillomavirus prevalence and type distribution among women attending routine gynecological examinations in Saudi Arabia by Abdulaziz AlObaid et al.
RESEARCH ARTICLE Open Access
Human papillomavirus prevalence and type
distribution among women attending routine
gynecological examinations in Saudi Arabia
Abdulaziz AlObaid1, Ismail A Al-Badawi2*, Hanan Al-Kadri3, Kusuma Gopala4, Walid Kandeil5, Wim Quint6,
Murad Al-Aker2,7 and Rodrigo DeAntonio5
Abstract
Background: Cervical cancer (CC) is caused by persistent infection with high-risk (HR) human papillomavirus (HPV)
types. In Saudi Arabia which has a population of 6.5 million women over the age of 15 years, approximately 152
new cases of CC are diagnosed and 55 women die from the disease annually. Nevertheless current epidemiological
data for HPV in this population are limited. This study evaluated the prevalence and type distribution of HPV and
documented the awareness of HPV infection and health-related behavior among Saudi and non-Saudi women
attending routine examination.
Methods: This was an observational, epidemiological cross-sectional study conducted between April 2010 and
December 2011 at three hospitals in Saudi Arabia. Cervical samples from women aged ≥15 years, who were attending
routine gynecological examinations were collected and tested for HPV-DNA by polymerase chain reaction and typed
using the SPF10 DEIA/LiPA25 system. Two questionnaires on health-related behavior and awareness of HPV infection
were completed.
Results: A total of 417 women, mean age (standard deviation) 41.9 (±10.4) years, were included in the final analysis, of
whom 77% (321/417) were Saudi nationals. HPV-DNA was detected in 9.8% women (41/417, 95% confidence interval
[CI]: 7.1-13.1). The prevalence of any HR-HPV by age was: 25–34 years: 3.0%; 35–44 years: 4.5%; 45–54 years: 3.2%;
>55 years: 10.9%. The most prevalent HR-HPV-types were: HPV-68/73 (5 cases); HPV-18 (4 cases); HPV-16 (3 cases). The
most prevalent low risk (LR) types were HPV-6 (4 cases); HPV-42, HPV-53 and HPV-54 (2 cases each). The prevalence of
HPV was higher among non-Saudi nationals vs. Saudi nationals (16.7% vs. 7.8%, P = 0.0234). No statistically significant risk
factors were identified: 32.2% (101/314) women were aware of HPV and 89.9% (285/317) showed an interest in HPV
vaccination.
Conclusion: The overall prevalence of HPV was 9.8% in Saudi Arabia, but was higher in women over 55 years, as well
as in non-Saudi nationals. These data provide a reference for public health authorities and may also help in determining
future policies for the prevention of CC.
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Background
Cervical cancer (CC) is the third most frequent cancer
in women throughout the world and was associated with
an estimated 530,000 new cases and 275,000 deaths in
2008 [1]. The global age standardized incidence rate for
CC is 15.2 per 100,000 population [2]. Saudi Arabia has
a population of 6.5 million women over the age of
15 years [3]. Based on the available data, around 152
women are diagnosed with CC and 55 die from the dis-
ease annually, corresponding to the 11th most frequent
cancer among women of all ages in this population [3].
However, as not all CC cases are reported in Saudi
Arabia, there is a concern that the real incidence of CC
may be somewhat higher.
It is known that CC is caused by persistent infection
with high-risk (HR) human papillomavirus (HPV) types
[4,5], of which HPV-16 and HPV-18 are responsible for
approximately 70% of the overall cases [6]. Two HPV
vaccines are currently licensed in many countries: a bi-
valent vaccine (Cervarix®, GlaxoSmithKline, Belgium)
and a quadrivalent vaccine (Gardasil®, Merck and Co.,
Inc., Whitehouse Station, New Jersey), both of which are
well-tolerated and have good efficacy profiles [7-14]. The
introduction of these vaccines provides an opportunity
to reduce CC, but the introduction of such a preventive
measure, requires baseline data on national epidemi-
ology and prevalent circulating HPV strains.
The epidemiology of HPV amongst women in Saudi
Arabia is not fully understood and only limited publica-
tions about the prevalence, detection and genotyping of
HPV [15-17] and attitudes towards screening are avail-
able in this population [18,19]. In order to bridge this
gap and provide baseline data, this study was undertaken
to evaluate the prevalence and type distribution of HPV,
including HR and low risk (LR)-types, among Saudi and
non-Saudi women. The study also documented the level
of awareness of HPV infection, health-related behavior,
and potential risk factors for HPV infection among
women attending routine gynecological screening.
Methods
Study design and study population
This multicenter, observational, cross-sectional, epidemio-
logical study (NCT01213459) was conducted between
April 2010 and December 2011 at three large hospitals:
King Fahd Medical City (KFMC), King Faisal Specialist
Hospital and Research Centre (KFSH and RC) and King
Abdulaziz Medical City-National Guard Health Affairs
(KAMC-NGHA) in Riyadh, Saudi Arabia. Women aged
≥15 years undergoing routine gynecological examination
and willing to provide a cervical sample were enrolled.
Pregnant women above 25 years or women with a known
diagnosis of immunosuppression, or those who had
undergone hysterectomy were excluded from the study.
Cytological examination of the collected cervical samples
was undertaken locally in the laboratories at each hos-
pital. The investigator issued two questionnaires for com-
pletion by all women; these assessed health-related
behavior and their awareness of HPV. The responses to
these questionnaires were anonymous and confidentiality
was maintained.
Sample collection and laboratory procedures
Endocervical samples were also collected during the first
visit by a trained practitioner/gynecologist using a cyto-
brush and placed in a liquid-based cytology transport
medium (PreservCyt®, ThinPrep Pap Test; Cytyc Corpor-
ation, Boxborough, Massachusetts). Samples were stored
at room temperature at the sites for four weeks and then
at −20°C until shipment to the DDL Diagnostic Labora-
tory (Rijswijk, The Netherlands).
DNA was isolated from 500 μl of the cervix-vagina on
a MagNA Pure Robot (Roche Diagnostics, Almere, The
Netherlands) using the MagNA Pure LC Total NAILV
kit and eluted in 50 μl of elution buffer [20]. Samples
were tested for HPV-DNA at DDL by broad-spectrum
polymerase chain reaction (PCR) using HPV short PCR
fragment 10 (SPF-10) and PCR DNA enzyme immuno-
assay (PCR-DEIA) to amplify and recognize at least 57
HPV genotypes by hybridization with a cocktail of nine
conservative probes. If positive by SPF10-DEIA the
amplimers were further analyzed by Line probe assay 25
(LiPA25) version 1 system (Labo Biomedical Products,
Rijswijk, The Netherlands). This Line probe assay 25
(LiPA25) version 1 system (Labo Biomedical Products,
Rijswijk, The Netherlands) was used to genotype 25 HR
and LR HPV types [21]. (The sequence variation within
the SPF10 inter-primer region did not allow HPV type 68
and 73 to be distinguished [22,23]). DEIA positive-LiPA
negative samples were denoted as non-typeable.
Sample size calculation
The primary objective of the study was to describe the
prevalence and types of HPV (including multiple infec-
tions) among women ≥15 years of age. To meet this ob-
jective, an estimated HPV prevalence ranging from 10 to
30% as previously reported [17,24,25], was considered.
Given a precision level of 0.045, the required number of
subjects ranged from 188 subjects for a 10% HPV preva-
lence to 450 subjects for a 30% prevalence, including an
assumption of 10% of subjects non-evaluable.
Statistical analyses
The percentage of women in each category who were
HPV positive was tabulated with corresponding 95%
confidence intervals (CI). Descriptive analyses regarding
HPV prevalence, HPV-types, age distribution, potential
risk factors (education level, life-time marital partners,
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parity and smoking status) and HPV status were per-
formed. An exploratory analysis was performed to assess
the association between the HPV status and nationality
(two sided Fisher’s exact test) and the adjusted odds ra-
tio (adjusted for factors which are associated with the
risk of HPV infection) was calculated using multivariate
logistic regression model. All statistical analyses were
performed using the statistical analysis software (SAS®)
version 9.2.
Ethical considerations
The study was approved by the following local ethics re-
view bodies: Institutional Review Board at KAMC-NGHA;
Institutional Review Board at KFMC; Research Ethics
Committee of Office of Research Affairs at KFSH and RC.
The study was conducted in accordance with the Declar-
ation of Helsinki, good clinical practice guidelines and
local rules and regulations of the country. A written in-
formed consent was obtained from all eligible women be-
fore entering the study. The investigator communicated
results as appropriate to the subjects, including the need
for additional testing or treatment.
Results
Study population
Of 420 enrolled women, 417 were included in the final
analysis (three were excluded: two due to pregnancy and
one due to hysterectomy). A total of 151, 152 and 117
women were enrolled at the KFMC, KFSH and RC, and
KAMC-NGHA hospitals, respectively. Overall, 319 women
completed the health-related behavior questionnaire and
317 completed the HPV awareness questionnaire. The
mean age (standard deviation) of the population was 41.9
(±10.45) years and 77% (321/417) were Saudi nationals.
Most women (93.1%, 297/319) were married and 63.0%
(201/319) had studied up to post-secondary/university
level.
Overall HPV prevalence and type distribution
HPV-DNA was detected in 41 out of 417 women (9.8%),
of whom 25 had single HPV-type infection, 4 had multiple
HPV-type infection and at least12 women were infected
with non-typeable HPV-types. Overall, the most prevalent
HR-HPV-types were HPV-68/73 (5 cases); HPV-18 (4
cases); HPV-16 (3 cases) and the most prevalent LR types
were HPV-6 (4 cases); HPV-42, HPV-53 and HPV-54 (2
cases each) (Table 1).
HPV prevalence and type distribution by age
The prevalence of any HR-HPV was highest (10.9%)
among women over 55 years; LR-HPV-types were also
found in 6.5% of this age group (Figure 1). However, no
statistical significance was noted by age group.
HPV prevalence and type distribution by nationality
The prevalence of HPV was higher (16.7% vs. 7.8%, P =
0.0234) among non-Saudi nationals (n = 96) as compared
with Saudi nationals (n = 321) respectively (Figure 2).
HPV co-infection
Multiple infections were observed in four women; three of
whom were infected with HR-HPV-68/73 (−68/73 with
−52, −39, −53; −68/73 with −40; and −68/73 with −54).
One woman had a co-infection of HR-HPV-16 with −31.
No HR-HPV-18 positive women were co-infected with
any other HR-HPV-types.
Table 1 HPV prevalence and type distribution (N = 417)
N = 417 n % 95% CI
HPV negative 376 90.2 86.9–92.9
HPV positive 41 9.8 7.1–13.1
Single infection 25 61.0 44.5–75.8
Multiple infection 4 9.8 2.7–23.1
Non-typeable# 12 29.3 16.1–45.5
HPV-types (n = 41)*
Any high-risk HPV** 18 43.9 28.5–60.3
HPV-68/73 5 12.2 4.1–26.2
HPV-18 4 9.8 2.7–23.1
HPV-16 3 7.3 1.5–19.9
HPV-31 2 4.9 0.6–16.5
HPV-51 2 4.9 0.6–16.5
HPV-52 2 4.9 0.6–16.5
HPV-39 1 2.4 0.1–12.9
HPV-56 1 2.4 0.1–12.9
HPV-58 1 2.4 0.1–12.9
Any low-risk HPV*** 14 34.1 20.1–50.6
HPV-6 4 9.8 2.7–23.1
HPV-42 2 4.9 0.6–16.5
HPV-53 2 4.9 0.6–16.5
HPV-54 2 4.9 0.6–16.5
HPV-11 1 2.4 0.1–12.9
HPV-40 1 2.4 0.1–12.9
HPV-70 1 2.4 0.1–12.9
HPV-74 1 2.4 0.1–12.9
N: number of women whose cervical samples were tested; n: number of
women in a given category; 95% CI: exact 95% confidence interval.
#DEIA positive-LiPA negative.
*Some women were infected with multiple HR/LR HPV types.
**Includes 14 women with single HR-HPV infection and 4 women with multiple
infections and at least one HR-HPV type.
***Includes 11 women with single LR-HPV infection and 3 women with
multiple infections and at least one LR-HPV type.
Note: Single infection = 25/417 = 6.0% (95% CI: 3.9–8.7); Multiple infection = 4/
417 = 0.9% (95% CI: 0.3–2.4); non-typeable = 12/417 = 2.9% (95% CI: 1.5–5.0).
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Awareness and health related behavior questionnaire
results
The potential risk factors of educational level, number of
life-time partners, parity and smoking status assessed
using univariate analyses showed no statistical associations
with any HPV infection (Table 2). Of 317 women complet-
ing the HPV awareness questionnaire, 101 (32.2%) were
aware of HPV and 285 (89.9%) expressed an interest in
vaccination (Table 3).
Discussion
This study estimated the prevalence and type distribution
of HPV in 417 women above 15 years of age attending
routine gynecological screening at three large hospitals in
Riyadh, Saudi Arabia. We reported a 9.8% prevalence for
HPV, which is much lower than the 31.6% overall
prevalence of HPV-16/18 reported previously in a small
study involving subjects from Riyadh [24]. An earlier re-
port from Jeddah reported a 5.6% prevalence of HR-types
[17]. These differences could be due to many factors in-
cluding differences in HPV testing technology, study size,
age groups or geographical variations. The study which
was undertaken in Riyadh [24] included a limited number
of subjects (75 Saudi nationals and 45 from other coun-
tries) from just one hospital (which was also included in
our study). The higher proportion of non-Saudi nationals
in this study might help to explain the observed higher
HPV prevalence [24]. Conversely, although the sample
size in the study conducted in Jeddah [17] was similar to
that in our present study, the exclusion of non-Saudi
nationals might explain the lower reported HPV preva-
lence. According to available data, our study included a
Figure 1 HPV prevalence and type distribution by age (N = 417*). *Note: For 2 women, dates were not available; hence age could not be
estimated. Note: The error bars represent 95% confidence intervals.
Figure 2 HPV prevalence and type distribution by nationality (N = 417). Note: The error bars represent 95% confidence intervals.
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representative number of Saudi and non-Saudi nationals,
which reflects the current demography of Saudi Arabia
[25]. This might explain higher HPV prevalence in our
study compared to the Jeddah study. Our study might
therefore be more representative of the current situation
in Saudi Arabia given the larger sample size as well as the
inclusion of non-Saudi nationals.
Indeed, data from the Saudi Cancer registry suggest
that there are regional differences in the percentage dis-
tribution of CC with the northern region having the
highest (6.4%) percentage distribution compared with
the other regions [26].
According to the United Nations classification, Saudi
Arabia belongs to the Western Asia region [27], which
has a lower HPV prevalence rate (2.2% [95% CI, 1.5–
3.1]) compared with global rates (11.4% [95% CI, 11.3–
11.5]) in women with normal cytology [2]. The crude
incidence rate of CC per 100,000 women per year in
Saudi Arabia is 1.3, which is lower than that in Western
Asia (3.6) and the world (15.8) [2]. The prevalence of
HPV in women with CC in Saudi Arabia has a broad
range (43–89%) [28,29] compared with the global preva-
lence (85–99%) [6]. The low rates of CC in Saudi Arabia
as compared with other countries could be due to differ-
ences in sexual practices and attitudes. For example, the
population in Saudi Arabia is more conservative than
western countries where most of the data derive [30].
The exact reasons for these low rates in Saudi Arabia
are not known, but highlight the need for recent data to
better understand the disease burden of HPV and the
prevalent circulating types.
The most prevalent HR-HPV-types reported in our
study were HPV-68/73, 18 and 16; the most common
LR-HPV-types were HPV-6, 42, 53 and 54. HPV-types
16 and 18 have been predominantly reported in HPV
infections globally and the results of our study were
therefore consistent [24,31]. We did however note a
high prevalence of HPV-68/73 for the first time, espe-
cially among non-Saudi nationals. HPV-68 type has
been reported throughout the world, with the exception
of North America, albeit at a lower prevalence [32].
However, our results should be considered with caution
as only five women were positive for HPV-68/73. Fu-
ture studies to substantiate this finding are therefore
indicated.
Our study also found that HR-HPV infection was high-
est (10.9%) in the oldest age group (>55 years). These re-
sults are consistent with the general worldwide trend of
higher HPV burden in older women. However, the com-
parator study from Bruni et al. [31] only included women
with normal cytology whereas the cytology status was not
known in the present study [32].
Table 2 Prevalence of any HPV by risk factors (N = 319)
Risk factors Categories N HPV+ % Adj. OR LL–UL P value
Age at sample collection (years) <30* 56 3 5.36 . . .
30-39 124 12 9.68 3.310 0.391–28.052 0.2723
40-49 132 12 9.09 2.097 0.230–19.085 0.5110
50-60 89 12 13.48 4.136 0.454–37.681 0.2079
>60 14 2 14.29 9.570 0.601–152.366 0.1097
Nationality Non-Saudi* 96 16 16.67 . . .
Saudi 321 25 7.79 0.315 0.116–0.855 0.0234
Education level No formal education* 21 2 9.52 . . .
Primary 47 3 6.38 1.039 0.144–7.489 0.9693
Secondary 50 4 8.00 1.515 0.200–11.492 0.6879
Post-secondary/University 201 24 11.94 1.158 0.180–7.447 0.8770
Number of marital partners 1* 286 29 10.14 . . .
2-5 32 4 12.50 1.129 0.324–3.941 0.8488
Parity 0* 8 0 0.00 . . .
1-2 100 11 11.00 >999.999 <0.001– > 999.999 0.9516
3-5 112 14 12.50 >999.999 <0.001– > 999.999 0.9502
≥ 6 71 5 7.04 >999.999 <0.001– > 999.999 0.9518
Smoking status No* 273 30 10.99 . . .
Yes 44 3 6.82 0.502 0.134–1.875 0.3053
N: number of subjects in a given cohort; %: HPV+/number of subjects with available results × 100; Adj. OR: Adjusted odds ration from simple logistic regression
model Odds ratio adjusted for the other variables; 95% CI: Wald 95% confidence interval; LL: lower limit; UL: upper limit.
*Reference category.
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We estimated a higher proportion of infection in non-
Saudi nationals compared with the Saudi nationals. This
difference could be due to many reasons including dif-
ferent cultural behaviors such as male circumcision
[32,33], sexual behavior or prevalence in the native
countries. Further studies are therefore warranted. Al-
though, it appears that non-Saudi nationals are at a
greater risk of contracting infection, prevalent HPV
types indeed pose a risk of infecting Saudi nationals.
Our study did not find educational level, number of life-
time partners, parity or smoking status to be signifi-
cantly associated risk factors for HPV-16, HPV-18 or
any HR-HPV infection.
Our study results should be interpreted with caution
as the study design was cross sectional, i.e., we obtained
single point estimates of women with HPV infections.
These infections could have been transient and resolved
on their own rather than leading to CC. In addition,
since the overall number of women positive for HPV it-
self was low, the prevalence of HPV types should be
interpreted with caution. Another limitation lies within
the recruitment process: women with higher levels of
education are more likely to opt for cervical cancer
screening and therefore would be more likely to partici-
pate in our study. Nevertheless, our study did also in-
clude women who did not have formal education.
A major strength of this study was the high quality of
HPV-DNA testing across the three hospitals in all age
groups which helps to provide a representative sample
of the population. The study also met the required sam-
ple size to calculate an overall prevalence of 9.8% with
Table 3 Awareness of HPV infection among women
(N = 317)
Characteristics Categories n %
How common is cervical cancer
in women?
Very common 48 15.1
Common 157 49.5
Rare 56 17.7
Not sure 56 17.7
What do you think is/are the
main reasons for cervical cancer?*
It develops from inside 95 30.0
Bacterial infection 49 15.5
Viral infection 80 25.2
None 14 4.4
Not sure 85 26.8





Rous sarcoma virus 23 7.3
Hereditary/genetic factors 115 36.3
None 18 5.7
Not sure 88 27.8
What do you think can turn
in to cervical cancer*
Genital warts 109 34.4
Bacterial infection 56 17.7
Fungal infection 26 8.2
None 23 7.3
Not sure 108 34.1
Apart from avoiding unwanted
pregnancy, what would you








No ill effect at all 77 24.3
Not sure 86 27.1
Did you hear about HPV before? Yes 101 32.2
No 213 67.8
Missing 3 -
If yes*, General physician 28 8.8




How is HPV transmitted?* Contaminated
food/Water
10 3.2
Mosquito bite 3 0.9
Sexually 159 50.2
None 20 6.3
Not sure 127 40.1
How is cervical cancer
diagnosed?*





Table 3 Awareness of HPV infection among women
(N = 317) (Continued)
All above 82 25.9
None 2 0.6
Not sure 30 9.5
Is it possible to prevent cancer? Yes 243 78.9
No 26 8.4
Not sure 39 12.7
Missing 9 -







Through condom use 14 4.4
If the vaccine against cervical
cancer is available, would you be
interested in getting vaccinated?
Yes 285 89.9
No 32 10.1
N: number of women in a specified category for whom questionnaire data
were collected.
*Women could have selected more than one option.
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good precision. Furthermore, the questionnaires were
completed by most enrolled women giving an important
insight into behavior and attitudes, and suggesting that
the introduction of a preventive measure such as vaccin-
ation would be accepted. Reports indicate that the pro-
portion of non-Saudi nationals represent 20%–30% of
the entire population in Saudi Arabia [25,34] which is
consistent with our results (23%). In addition, the pro-
portion of women completing up to post-secondary/uni-
versity level education in our study (63%) is comparable
to the Organization for Economic Co-operation and
Development (OECD) reports, where at least 50% of
women were educated and at least 54% of women
among all OECD countries completed post-secondary
education [35]. These comparisons therefore indicate
the representativeness of our study population.
The study results emphasize the need for a future up-
dated policy for HPV and CC prevention in Saudi Arabia.
A World Health Organization document on cancer con-
trol in the Eastern Mediterranean region describes that
only 35% of CC cases present at early stage; as in other de-
veloping countries, the rest are reported at later stages
when cure is unlikely, even with the best treatment [34]. It
has also been reported that when women are double nega-
tive in the conventional cytological screening test and the
highly sensitive HPV molecular test, then screening can
be performed at longer intervals [36]. Our study findings
together with these data will help determine the best strat-
egy for targeting preventive interventions, and designing
public health measures for Saudi Arabia.
Conclusion
The overall results from this study emphasize that the HPV
burden in Saudi Arabia is a cause for concern and prevent-
ive strategies such as screening, HPV-DNA testing of cer-
vical samples and vaccination might reduce the burden of
the disease. Our data can raise the awareness of local au-
thorities and public health officials and help to guide policy
in Saudi Arabia to implement strategies to prevent CC.
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